NASDAQ:TSRO - Tesaro Stock Price, Price Target & More

Question 1

What is Tesaro's stock symbol?

Answer

Tesaro trades on the NASDAQ under the ticker symbol "TSRO."

Question 2

How were Tesaro's earnings last quarter?

Answer

Tesaro (NASDAQ:TSRO) issued its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.56) by $0.42. The biopharmaceutical company earned $49.74 million during the quarter, compared to analyst estimates of $56.34 million. Tesaro had a negative return on equity of 177.92% and a negative net margin of 193.42%. The firm's quarterly revenue was up 1520.2% on a year-over-year basis. During the same period in the previous year, the business posted ($2.55) earnings per share. View Tesaro's Earnings History.

Question 3

When is Tesaro's next earnings date?

Answer

Tesaro is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Tesaro.

Question 4

What price target have analysts set for TSRO?

Answer

23 equities research analysts have issued 12-month target prices for Tesaro's stock. Their predictions range from $48.00 to $199.00. On average, they anticipate Tesaro's stock price to reach $119.00 in the next twelve months. View Analyst Ratings for Tesaro.

Question 5

What are Wall Street analysts saying about Tesaro stock?

Answer

Here are some recent quotes from research analysts about Tesaro stock:

1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (5/3/2018)
2. Cann analysts commented, "Tesaro released Q4 2017 results today with better than expected Zejula sales and higher than estimated R&D. Due to a certain amount of confusion and competition in the PARP market, we are adjusting our outlook to accommodate a slower adoption of Zejula, which is leading us to lower our target price from $199 to $122. We believe Zejula has the strongest data in the ovarian cancer maintenance setting and upside that could result from label expansion in other tumor types." (2/27/2018)
3. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)
4. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)

Question 6

Who are some of Tesaro's key competitors?

Answer

Some companies that are related to Tesaro include BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR) and Taro Pharmaceutical Industries (TARO).

Question 7

Who are Tesaro's key executives?

Answer

Tesaro's management team includes the folowing people:

Mr. Leon O. Moulder Jr., Co-Founder, Chief Exec. Officer and Director (Age 61)
Dr. Mary Lynne Hedley, Co-Founder, Pres, Chief Operating Officer and Director (Age 55)
Mr. Timothy R. Pearson, Chief Financial Officer and Exec. VP (Age 50)
Dr. Jeffrey H. Hanke Ph.D., Chief Scientific Officer and Exec. VP of R&D (Age 61)
Dr. Martin H. Huber Jr., M.D., Chief Medical Officer and Sr. VP (Age 58)

Question 8

Has Tesaro been receiving favorable news coverage?

Answer

News coverage about TSRO stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tesaro earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.10 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Question 9

Who are Tesaro's major shareholders?

Answer

Tesaro's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (19.01%), BlackRock Inc. (7.28%), BB Biotech AG (2.97%), Rock Springs Capital Management LP (1.05%), Millennium Management LLC (0.88%) and EULAV Asset Management (0.54%). Company insiders that own Tesaro stock include David M Mott, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Leon O Moulder Jr, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira, Peter J Barris and Timothy R Pearson. View Institutional Ownership Trends for Tesaro.

Question 10

Which institutional investors are selling Tesaro stock?

Answer

TSRO stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Dimensional Fund Advisors LP, BlackRock Inc., Principal Financial Group Inc., Principal Financial Group Inc., Eversept Partners LLC, Spark Investment Management LLC and Swiss National Bank. Company insiders that have sold Tesaro company stock in the last year include Edward C English, Grant C Bogle, James O Armitage, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira and Timothy R Pearson. View Insider Buying and Selling for Tesaro.

Question 11

Which institutional investors are buying Tesaro stock?

Answer

TSRO stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, Frontier Capital Management Co. LLC, State of New Jersey Common Pension Fund D, EULAV Asset Management, Millennium Management LLC, NEA Management Company LLC, Bellevue Group AG and DekaBank Deutsche Girozentrale. Company insiders that have bought Tesaro stock in the last two years include David M Mott, Enterprise Associates 13 L New, Leon O Moulder Jr and Peter J Barris. View Insider Buying and Selling for Tesaro.

Question 12

How do I buy shares of Tesaro?

Answer

Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 13

What is Tesaro's stock price today?

Answer

One share of TSRO stock can currently be purchased for approximately $47.24.

Question 14

How big of a company is Tesaro?

Answer

Tesaro has a market capitalization of $2.62 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. Tesaro employs 715 workers across the globe.

Question 15

How can I contact Tesaro?

Answer

Tesaro's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		486 (Vote Outperform)
Underperform Votes:		326 (Vote Underperform)
Total Votes:		812

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.65	2.61	2.58	2.58
Ratings Breakdown:	0 Sell Rating(s) 8 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$119.00	$129.2609	$148.7391	$161.00
Price Target Upside:	151.91% upside	118.97% upside	134.23% upside	87.43% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/7/2018	Lake Street Capital	Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $80.00	High
5/4/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$94.00 ➝ $88.00	Low
5/4/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$141.00 ➝ $128.00	Low
5/4/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$102.00 ➝ $100.00	Low
5/3/2018	Piper Jaffray Companies	Lower Price Target	Neutral	$50.00	High
5/2/2018	Argus	Lower Price Target	Buy ➝ Buy	$154.00 ➝ $110.00	Medium
4/24/2018	Robert W. Baird	Reiterated Rating	Hold		Low
3/27/2018	HC Wainwright	Reiterated Rating	Buy	$108.00	High
3/1/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$156.00 ➝ $146.00	Low
2/28/2018	Wells Fargo	Reiterated Rating	Outperform	$224.00 ➝ $122.00	Medium
2/28/2018	Leerink Swann	Reiterated Rating	Outperform	$123.00 ➝ $105.00	High
2/28/2018	Royal Bank of Canada	Lower Price Target	Sector Perform	$48.00	High
2/28/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $90.00	High
2/27/2018	Cann	Reiterated Rating	Buy	$199.00 ➝ $122.00	Medium
2/22/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform	$88.00	High
1/2/2018	Cowen	Lower Price Target	Market Perform	$125.00 ➝ $80.00	Low
11/10/2017	SunTrust Banks	Reiterated Rating	Buy	$160.00	N/A
11/3/2017	Jefferies Group	Reiterated Rating	Hold	$124.00	N/A
9/11/2017	Wedbush	Reiterated Rating	Outperform	$160.00	Low
9/10/2017	Oppenheimer	Reiterated Rating	Buy	$199.00	Low
7/14/2017	Janney Montgomery Scott	Reiterated Rating	Neutral		Low
7/7/2017	Gabelli	Initiated Coverage	Buy	$175.00	High
6/20/2017	Raymond James	Reiterated Rating	Market Perform		Medium
6/5/2017	FBR & Co	Lower Price Target	Mkt Perform ➝ Mkt Perform	$200.00 ➝ $195.00	High
11/4/2016	UBS	Downgrade	Outperform ➝ Market Perform		N/A
8/5/2016	Mizuho	Lower Price Target	Buy	$100.00 ➝ $94.00	N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	($3.15)	($2.52)	($2.85)
Q2 2018	5	($2.63)	($1.99)	($2.38)
Q3 2018	5	($2.74)	($1.68)	($2.26)
Q4 2018	5	($2.58)	($1.32)	($2.04)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		($2.64)					N/A
5/3/2018	Q1 2018	($2.56)	($2.98)	$56.34 million	$49.74 million	View	N/A
2/27/2018	Q4 2017	($2.39)	($3.35)	$51.78 million	$48.02 million	View	Listen
11/7/2017	Q3 2017	($1.16)	($0.4660)	$130.57 million	$142.77 million	View	N/A
8/8/2017	Q2 2017	($2.52)	($2.82)	$18.61 million	$29.50 million	View	Listen
5/9/2017	Q1 2017	($2.26)	($2.55)	$3.84 million	$3.10 million	View	Listen
2/28/2017	Q4 2016	($1.96)	($2.60)	$5.60 million	$4.23 million	View	N/A
11/3/2016	Q3	($1.92)	($1.98)	$4.39 million	$3.73 million	View	N/A
8/4/2016	Q2 2016	($1.69)	($1.28)	$10.49 million	$36.56 million	View	N/A
5/5/2016	Q1	($1.69)	($2.22)	$2.48 million	$0.31 million	View	N/A
2/25/2016	Q4	($1.63)	($1.89)	$3.45 million	$0.23 million	View	Listen
10/29/2015	Q315	($1.52)	($1.66)		$0.09 million	View	Listen
8/6/2015	Q215	($1.14)	($1.51)			View	Listen
4/30/2015	Q115	($1.12)	($1.30)			View	Listen
2/19/2015	Q414	($1.03)	($1.33)			View	Listen
11/5/2014	Q314	($1.04)	($1.01)			View	N/A
7/24/2014	Q214	($0.87)	($1.03)			View	N/A
4/30/2014	Q114	($1.06)	($1.43)			View	N/A
2/19/2014	Q413	($0.78)	($0.72)			View	N/A
11/7/2013	Q313	($0.69)	($0.88)			View	N/A
7/25/2013	Q2 2013	($0.63)	($0.67)			View	N/A
4/25/2013	Q1 2013	($0.62)	($0.66)			View	N/A
2/14/2013	Q4 2012	($0.65)	($15.41)			View	N/A
10/25/2012		($0.55)	($0.52)			View	N/A
7/26/2012		($0.55)	($4.11)			View	N/A

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2018	Orlando Oliveira	SVP	Sell	3,000	$69.88	$209,640.00	9,076
3/6/2018	Peter J Barris	Major Shareholder	Buy	145,532	$57.40	$8,353,536.80	252
3/5/2018	David M Mott	Director	Buy	61,437	$58.83	$3,614,338.71	12,825
3/2/2018	David M Mott	Director	Buy	68,302	$55.56	$3,794,859.12	12,825
3/2/2018	Enterprise Associates 13 L New	Major Shareholder	Buy	54,642	$55.56	$3,035,909.52	252
3/2/2018	Leon O Moulder Jr	CEO	Buy	5,000	$56.93	$284,650.00	1,018,828
3/2/2018	Martin H Jr. Huber	SVP	Sell	1,803	$54.86	$98,912.58	11,647
3/2/2018	Timothy R Pearson	CFO	Sell	2,575	$54.86	$141,264.50	7,303
3/1/2018	Grant C. Bogle	VP	Sell	1,809	$54.85	$99,223.65
3/1/2018	Mary Lynne Hedley	COO	Sell	3,855	$54.86	$211,485.30	16,073
12/4/2017	Martin H Jr. Huber	SVP	Sell	829	$85.24	$70,663.96	8,101
9/22/2017	Martin H Jr. Huber	SVP	Sell	592	$118.60	$70,211.20	6,943
9/18/2017	James O Armitage	Director	Sell	10,000	$117.13	$1,171,300.00	10,000
9/6/2017	Edward C English	VP	Sell	10,862	$134.92	$1,465,501.04	6,258
9/5/2017	Orlando Oliveira	SVP	Sell	71	$132.66	$9,418.86	6,626
9/1/2017	Grant C. Bogle	VP	Sell	14,167	$135.00	$1,912,545.00
6/6/2017	Edward C English	VP	Sell	8,500	$138.65	$1,178,525.00	5,396
4/3/2017	Martin H Jr. Huber	SVP	Sell	829	$153.02	$126,853.58	6,522
3/6/2017	Edward C English	VP	Sell	10,000	$178.06	$1,780,600.00	5,396
3/2/2017	Edward C English	VP	Sell	229	$177.61	$40,672.69	625
3/2/2017	Grant C. Bogle	SVP	Sell	1,447	$177.61	$257,001.67
3/2/2017	Mary Lynne Hedley	COO	Sell	3,927	$177.61	$697,474.47	10,000
1/3/2017	Martin H. Jr. Huber	SVP	Sell	190	$136.26	$25,889.40
11/2/2016	Martin H Jr. Huber	SVP	Sell	327	$121.29	$39,661.83	1,842
9/22/2016	Martin H Jr. Huber	SVP	Sell	408	$108.12	$44,112.96	1,250
9/8/2016	Edward C English	VP	Sell	7,000	$88.54	$619,780.00	3,500
8/30/2016	Jeffrey H Hanke	VP	Sell	29,166	$86.04	$2,509,442.64	29,166
6/30/2016	Jeffrey H Hanke	VP	Sell	12,500	$74.35	$929,375.00	12,500
6/10/2016	Edward C English	VP	Sell	7,000	$40.75	$285,250.00	3,500
3/18/2016	Arnold L Oronsky	Director	Buy	142,085	$35.19	$4,999,971.15	2,479
3/18/2016	Enterprise Associates 13 L New	Major Shareholder	Buy	710,429	$35.19	$24,999,996.51
3/10/2016	Edward C English	VP	Sell	7,000	$43.71	$305,970.00	3,500
12/10/2015	Edward C. English	VP	Sell	17,000	$50.19	$853,230.00
9/8/2015	James O Armitage	Director	Buy	500	$54.63	$27,315.00
12/12/2014	James O Armitage	Director	Buy	1,000	$38.16	$38,160.00
9/29/2014	Lawrence M Alleva	Director	Buy	1,100	$26.17	$28,787.00
7/31/2013	Lawrence M Alleva	Director	Buy	1,449	$34.33	$49,744.17
6/5/2013	Peter J Barris	Major Shareholder	Sell	3,583	$39.00	$139,737.00
4/30/2013	Lawrence M Alleva	Director	Buy	1,050	$28.10	$29,505.00
11/1/2012	Lawrence M Alleva	Director	Buy	3,240	$15.45	$50,058.00
8/30/2012	Leon O Moulder Jr	CEO	Buy	10,000	$11.69	$116,900.00

Date	Headline
	Stock Performance Review on Tesaro and Three Other Biotech Industry finance.yahoo.com - May 21 at 8:38 AM
	$64.66 Million in Sales Expected for Tesaro (TSRO) This Quarter www.americanbankingnews.com - May 20 at 7:28 AM
	Tesaro Target of Unusually Large Options Trading (TSRO) www.americanbankingnews.com - May 18 at 7:41 AM
	Tesaro Target of Unusually High Options Trading (TSRO) www.americanbankingnews.com - May 18 at 6:46 AM
	Analysts Expect Tesaro (TSRO) Will Post Earnings of -$2.66 Per Share www.americanbankingnews.com - May 18 at 1:24 AM
	Oppenheimer Reiterates Outperform on TESARO (TSRO) Following Abstract Data Release www.streetinsider.com - May 17 at 8:32 AM
	TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual ... www.globenewswire.com - May 16 at 5:31 PM
	TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - May 16 at 5:31 PM
	Clovis May 2018 Update seekingalpha.com - May 16 at 8:59 AM
	Former Biotech Darlings Tesaro, Clovis Pin Hopes on 2018 Rebound finance.yahoo.com - May 10 at 5:22 PM
	Brokers Set Expectations for Tesaro's FY2018 Earnings (TSRO) www.americanbankingnews.com - May 10 at 7:59 AM
	With A -24.35% Earnings Drop, Is Tesaro Inc’s (NASDAQ:TSRO) A Concern? finance.yahoo.com - May 9 at 5:25 PM
	Psychological Effects of Ovarian Cancer Often Overlooked and Can Have a Significant Impact on Patients finance.yahoo.com - May 8 at 5:27 PM
	Tesaro (TSRO) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - May 7 at 7:24 PM
	Tesaro (TSRO) Receives "Buy" Rating from Lake Street Capital www.americanbankingnews.com - May 7 at 2:57 PM
	Tesaro (TSRO) to Post FY2021 Earnings of $6.57 Per Share, Oppenheimer Forecasts www.americanbankingnews.com - May 7 at 5:20 AM
	Brokers Set Expectations for Tesaro's FY2021 Earnings (TSRO) www.americanbankingnews.com - May 7 at 5:16 AM
	TESARO's (TSRO) CEO Lonnie Moulder on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 4 at 5:31 PM
	Tesaro (TSRO) Price Target Lowered to $88.00 at Bank of America www.americanbankingnews.com - May 4 at 3:57 PM
	Tesaro (TSRO) Price Target Cut to $100.00 www.americanbankingnews.com - May 4 at 3:57 PM
	Tesaro (TSRO) Price Target Cut to $128.00 www.americanbankingnews.com - May 4 at 3:57 PM
	Tesaro (TSRO) Issues Quarterly Earnings Results, Misses Expectations By $0.42 EPS www.americanbankingnews.com - May 4 at 3:32 PM
	BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98 www.reuters.com - May 4 at 8:20 AM
	Edited Transcript of TSRO earnings conference call or presentation 3-May-18 8:15pm GMT finance.yahoo.com - May 4 at 8:20 AM
	Tesaro Q1 Zejula sales $48.9M; sales outlook raised; shares down 1% premarket on revenue miss seekingalpha.com - May 4 at 7:31 AM
	Tesaro (TSRO) Lifted to "Hold" at Zacks Investment Research www.americanbankingnews.com - May 3 at 10:34 PM
	Tesaro (TSRO) Price Target Cut to $50.00 by Analysts at Piper Jaffray www.americanbankingnews.com - May 3 at 10:13 PM
	TESARO Announces First-Quarter 2018 Operating Results finance.yahoo.com - May 3 at 5:22 PM
	Tesaro: 1Q Earnings Snapshot finance.yahoo.com - May 3 at 5:22 PM
	Tesaro (TSRO) Price Target Cut to $110.00 www.americanbankingnews.com - May 2 at 10:16 AM
	$56.64 Million in Sales Expected for Tesaro (TSRO) This Quarter www.americanbankingnews.com - May 2 at 2:58 AM
	Zacks: Brokerages Anticipate Tesaro (TSRO) Will Announce Earnings of -$2.76 Per Share www.americanbankingnews.com - April 30 at 1:16 PM
	Tesaro (TSRO) Scheduled to Post Earnings on Monday www.americanbankingnews.com - April 30 at 7:23 AM
	Robert W. Baird Reaffirms Hold Rating for Tesaro (TSRO) www.americanbankingnews.com - April 24 at 1:22 PM
	BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula www.reuters.com - April 24 at 8:16 AM
	TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA® finance.yahoo.com - April 24 at 8:16 AM
	Lake Street Capital Analysts Give Tesaro (TSRO) a $120.00 Price Target www.americanbankingnews.com - April 23 at 9:18 AM
	Tesaro's (TSRO) "Outperform" Rating Reaffirmed at Wells Fargo www.americanbankingnews.com - April 20 at 8:01 PM
	Bank of America Reiterates "Buy" Rating for Tesaro (TSRO) www.americanbankingnews.com - April 20 at 8:00 PM
	Tesaro (TSRO) Downgraded by BidaskClub to Strong Sell www.americanbankingnews.com - April 20 at 11:17 AM
	TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018 finance.yahoo.com - April 19 at 5:40 PM
	Tesaro Sees Unusually Large Options Volume (TSRO) www.americanbankingnews.com - April 18 at 7:02 AM
	Tesaro Sees Unusually High Options Volume (TSRO) www.americanbankingnews.com - April 18 at 7:02 AM
	ValuEngine Lowers Tesaro (TSRO) to Sell www.americanbankingnews.com - April 17 at 10:21 PM
	Tesaro (TSRO) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 17 at 12:21 PM
	Today’s Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO finance.yahoo.com - April 17 at 8:26 AM
	TESARO (TSRO) Reports Summarized Initial Data from Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody) www.streetinsider.com - April 16 at 5:28 PM
	BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR www.reuters.com - April 16 at 9:15 AM
	TESARO Summarizes TSR-042 Clinical Data Presented at AACR globenewswire.com - April 16 at 9:15 AM
	Tesaro Expected to Earn FY2020 Earnings of ($1.94) Per Share (TSRO) www.americanbankingnews.com - April 16 at 3:03 AM

NASDAQ:TSRO - Tesaro Stock Price, Price Target & More

About Tesaro (NASDAQ:TSRO)

Receive TSRO News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Tesaro (NASDAQ:TSRO) Frequently Asked Questions

What is Tesaro's stock symbol?

How were Tesaro's earnings last quarter?

When is Tesaro's next earnings date?

What price target have analysts set for TSRO?

What are Wall Street analysts saying about Tesaro stock?

Who are some of Tesaro's key competitors?

Who are Tesaro's key executives?

Has Tesaro been receiving favorable news coverage?

Who are Tesaro's major shareholders?

Which institutional investors are selling Tesaro stock?

Which institutional investors are buying Tesaro stock?

How do I buy shares of Tesaro?

What is Tesaro's stock price today?

How big of a company is Tesaro?

How can I contact Tesaro?

MarketBeat Community Rating for Tesaro (TSRO)

Analyst Ratings

Tesaro (NASDAQ:TSRO) Price Target and Consensus Rating

Tesaro (NASDAQ:TSRO) Consensus Price Target History

Tesaro (NASDAQ:TSRO) Analyst Ratings History

Earnings

Tesaro (NASDAQ:TSRO) Earnings History and Estimates Chart

Tesaro (NASDAQ:TSRO) Earnings Estimates

Tesaro (NASDAQ TSRO) Earnings History by Quarter

Dividends

Tesaro (NASDAQ:TSRO) Dividend History by Quarter

Insider Trades

Tesaro (NASDAQ TSRO) Insider Trading and Institutional Ownership History

Tesaro (NASDAQ TSRO) Insider Trading History

Headlines

Tesaro (NASDAQ TSRO) News Headlines

SEC Filings

Tesaro (NASDAQ:TSRO) SEC Filings

Social Media

Financials

Tesaro (NASDAQ:TSRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tesaro (NASDAQ TSRO) Stock Chart for Monday, May, 21, 2018